# A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

> **NCT06422884** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Endeavor Biomedicines, Inc.** · enrollment: 213 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Progressive Fibrosing Interstitial Lung Disease

## Interventions

- **DRUG:** ENV-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06422884
- **Lead sponsor:** Endeavor Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422884, "A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06422884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*